Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:41:38.704Z.
Consensus retrieved: 2026-10-06T10:08:37.452Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:41:38.704Z.
Quote observation: 2026-10-06T16:40:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8816454c8f8663c3bedc847144af8f107147f6cc2e90a46c8541497c2a45775
Forward PE Ratio (N/A) = Dated Quote Price ($64.77) / Consensus Forward EPS ($-3.32)
FORWARD PE RATIO
N/A
CG Oncology Inc.
Market Cap
$5.71B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CG Oncology Inc. (CGON) | $5.71B | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.75B | 54.13 |
| RadNet, Inc. (RDNT)vs › | $5.54B | 137.07 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 29.17 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.91B | 31.66 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.92B | N/A |
| GRAIL Inc. (GRAL)vs › | $6.05B | N/A |
| Doximity, Inc. (DOCS)vs › | $5.33B | 21.14 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | 50.20 |
| Sotera Health Company (SHC)vs › | $5.28B | 18.79 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $64.77, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.32 | $-3.61 – $-3.10 | 11 | n/m |
| 2027-12-31 | $-3.13 | $-3.64 – $-2.16 | 11 | n/m |
| 2028-12-31 | $-0.90 | $-2.57 – $0.69 | 12 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
